



Name	Shang-Chin Huang
Affiliation	National Taiwan University Hospital Bei-hu Branch National Taiwan University Hospital National Taiwan University College of Medicine
Country	Taiwan
Major Field	HBV and MASLD

Educational Background

2007-2014: M.D., College of Medicine, National Yang-Ming University, Taipei, Taiwan
2021-now: Ph.D. student, Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Professional Experience

- 2022 Asian Pacific Association for the Study of the Liver (APASL) STC on HCC: Young Investigator Award 1st prize
- 2022 APASL STC on HCC: Outstanding Abstract Award
- 2022 Liver Disease Prevention & Treatment Research Foundation: Liver Disease Research Award
- 2022 Taiwan Digestive Disease Week (TDDW): Young Investigator Award 1st prize
- 2023 APASL Annual Meeting: Young Investigator Award 3rd prize
- 2023 APASL Annual Meeting: The Best Poster of YI
- 2023 TDDW: Young Investigator Award 1st prize
- 2024 APASL STC on MAFLD: Young Investigator Award
- 2024 Taiwan Association for the Study of the Liver (TASL) Distinguished Young Scholar Award
- 2024 Asian Pacific Association of Gastroenterology (APAGE) Research Programme Award (Co-investigator)
- 2025 APASL - Rising Star Award
- 2025 East Asia Liver Alliance (EALA) - Rising Star Bootcamp Best Presentation Award
- 2025 Prof. Juei-Low Sung's Research Foundation - Outstanding Research Article Award
- 2025 TASL Annual Meeting: Young Investigator Award
- 2025 American Association for the Study of Liver Diseases (AASLD) The Liver Meeting (TLM) - Poster of Distinction

Main Scientific Publications

- **SC Huang**, TH Su, TC Tseng, SJ Hsu, CM Hong, TY Lan, CH Liu, HC Yang, CJ Liu, JH Kao. All-cause and cause-specific mortality in patients with chronic hepatitis B and concurrent steatotic liver disease. *J Hepatol*. 2025 Jul;83(1):43-51.
- **SC Huang**, TH Su, TC Tseng, SH Liao, SJ Hsu, CM Hong, TY Lan, CH Liu, HC Yang, CJ Liu, JH Kao. Pre-Existing and New-Onset Metabolic Dysfunctions Increase Cirrhosis and Its Complication Risks in Chronic Hepatitis B. *Am J Gastroenterol*. 2025 Feb 1;120(2):401-409.
- **SC Huang**, TH Su, TC Tseng, CL Chen, SJ Hsu, CH Liu, SH Liao, CM Hong, TY Lan, HC Yang, CJ Liu, PJ Chen, JH Kao. Metabolic Dysfunction-Associated Steatotic Liver Disease Facilitates Hepatitis B Surface Antigen Seroclearance and Seroconversion. *Clin Gastroenterol Hepatol*. 2024 Mar;22(3):581-590.e6.
- **SC Huang**, TH Su, TC Tseng, CL Chen, SJ Hsu, SH Liao, CM Hong, CH Liu, TY Lan, HC Yang, CJ Liu, PJ Chen, JH Kao. Distinct effects of hepatic steatosis and metabolic dysfunction on the risk of hepatocellular carcinoma in chronic hepatitis B. *Hepatol Int*. 2023 Oct;17(5):1139-1149.
- **SC Huang**, TH Su. Divergent Roles of MASLD Components in Chronic Hepatitis B: A Double-Edged Sword.



J Hepatol. 2025 Feb 28;S0168-8278(25)00144-8.

- **SC Huang**, JH Kao. Viral Load-Based Prediction of Hepatocellular Carcinoma Risk in Noncirrhotic Patients With Chronic Hepatitis B. *Ann Intern Med.* 2025 Sep;178(9):1364.
- **SC Huang**, CJ Liu. Chronic hepatitis B with concurrent metabolic dysfunction-associated fatty liver disease: Challenges and perspectives. *Clin Mol Hepatol.* 2023 Apr;29(2):320-331.
- **SC Huang**, JH Kao. Hepatitis D Virus Infection. *N Engl J Med.* 2023 Oct 12;389(15):1441
- **SC Huang**, JH Kao. Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B. *Hepatology.* 2023 Mar 20. doi: 10.1097/HEP.0000000000000371.
- **SC Huang**, CJ Liu, JH Kao. Impact of metabolic disorders on chronic hepatitis B. *Clin Liver Dis (Hoboken).* 2024 Apr 4;23(1):e0130.
- **SC Huang**, JH Kao. The interplay between chronic hepatitis B and diabetes mellitus. *Kaohsiung J Med Sci.* 2024 Jan;40(1):6-10.
- **SC Huang**, JH Kao. Metabolic Health in Antiviral Era of Chronic Hepatitis B. *Clin Mol Hepatol.* 2025 Apr 11. doi: 10.3350/cmh.2025.0369.
- **SC Huang**, JH Kao. Breaking the Chain of Perinatal Hepatitis B Transmission. *Clin Mol Hepatol.* 2025 Jul 28. doi: 10.3350/cmh.2025.0801.
- **SC Huang**, JH Kao. Combining therapeutic agents to target the immune systems of hepatitis B patients: what do we need to consider? *Expert Rev Gastroenterol Hepatol.* 2025 Apr;19(4):371-375.
- **SC Huang**, JH Kao. Advancing Metabolic Risk Profiling in Chronic Hepatitis B. *Clin Mol Hepatol.* 2025 May 13. doi: 10.3350/cmh.2025.0500.
- **SC Huang**, HJ Su, JH Kao, TC Tseng, HC Yang, TH Su, PJ Chen, CJ Liu: Clinical and Histologic Features of Patients with Biopsy-Proven Metabolic Dysfunction-Associated Fatty Liver Disease. *Gut and Liver.* 2021 May 15;15(3):451-458.
- **SC Huang**, JH Kao: Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B. *Journal of the Formosan Medical Association.* 2022 Aug 15;S0929-6646(22)00286-8.
- **SC Huang**, PN Cheng, CH Liu, HC Yang, TH Su, TC Tseng, PJ Chen, JH Kao, CJ Liu: Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents. *Journal of the Formosan Medical Association.* 2022 May;121(5):920-929.
- **SC Huang**, JH Kao: Strategies for hepatitis C virus treatment failure. *Journal of the Formosan Medical Association.* 2022 May;121(5):876-878.
- **SC Huang**, JD Liang, SJ Hsu, TC Hong, HC Yang, JH Kao: Direct comparison of biopsy techniques for hepatic malignancies. *Clin Mol Hepatol.* 2021 Apr;27(2):305-312.
- **SC Huang**, SH Liao, TH Su, YM Jeng, JH Kao: Clinical manifestations and outcomes of patients with scirrhous hepatocellular carcinoma. *Hepatol Int.* 2021 Apr;15(2):472-481.
- **SC Huang**, JH Kao: Letter: hepatic steatosis and fibrosis in chronic hepatitis B-the chicken-and-egg conundrum. *Alimentary Pharmacology & Therapeutics.* 2022 Jan;55(1):143-144.
- **SC Huang**, JH Kao: Management of Hepatitis B in Persons Who Inject Drugs (PWID). *Current Hepatology Reports.* 2021 Oct 19; 20:158-165.